Owkin, an AI company dedicated to unraveling the complexity of biology, has announced a strategic collaboration with NVIDIA to advance the development of OwkinZero, its biological large reasoning model. The partnership aims to accelerate progress toward Biological Artificial Super Intelligence (BASI) by leveraging NVIDIA’s cutting-edge AI infrastructure, open models, and technical expertise. Through this collaboration, Owkin will integrate NVIDIA’s Nemotron family of open models and the NVIDIA NeMo framework into its AI development pipeline. A key component of the effort is the use of NVIDIA NeMo RL, an open-source reinforcement learning library within the NeMo ecosystem, which will enhance the customization, performance, and scalability of OwkinZero. This will strengthen the model’s reasoning capabilities, robustness, and safety guardrails—critical for high-stakes applications in drug discovery and development. The upgraded OwkinZero model will power the next generation of agentic AI systems within Owkin’s interoperable AI infrastructure, Owkin K. This platform serves as an AI copilot for biopharmaceutical researchers, clinicians, and drug developers, enabling them to explore complex biological questions, validate scientific hypotheses, and accelerate the path from discovery to treatment. Thomas Clozel, M.D., co-founder and CEO of Owkin, emphasized the importance of infrastructure in achieving BASI. “Building the first Biological Artificial Super Intelligence requires more than just powerful models—it demands the right agentic infrastructure and toolkits to scale them effectively,” Clozel said. “Our collaboration with NVIDIA is a pivotal step in creating the intelligent foundation for biology. By combining NVIDIA’s world-class AI ecosystem with Owkin’s domain-specific biological reasoning and access to proprietary multimodal patient data, we’re unlocking the ability to understand and reason about biological systems at an unprecedented scale.” This marks Owkin’s first major partnership with NVIDIA and represents a significant milestone in the company’s mission to transform how science discovers cures. The collaboration underscores a shared vision between Owkin and NVIDIA to advance AI-driven biological research, improve clinical success rates, and deliver life-saving therapies faster. Owkin continues to pioneer the integration of large language models, multimodal data, and autonomous AI agents to address some of the most complex challenges in medicine. With Owkin K and OwkinZero at its core, the company is building a new paradigm for scientific discovery—one where AI doesn’t just assist researchers, but actively collaborates with them to accelerate breakthroughs in human health.